# Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment

> **NCT07007962** · PHASE3 · RECRUITING · sponsor: **Sanofi** · enrollment: 60 (estimated)

## Conditions studied

- Immune Thrombocytopenia

## Interventions

- **DRUG:** rilzabrutinib

## Key facts

- **NCT ID:** NCT07007962
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-24
- **Primary completion:** 2027-11-05
- **Final completion:** 2028-12-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07007962

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07007962, "Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07007962. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*